TAP Pharmaceutical to settle claims, pay $150 million
January 6, 2005
TAP Pharmaceutical Products agreed to settle claims that consumers and private insurers overpaid for the LHRH hormone analog leuprolide acetate (Lupron), according to a report in The Boston Globe.
